Androgen depletion/repletion in combination with chemotherapy: strategy for secondary treatment of metastatic prostatic cancer.
作者信息
Santen R J, English H, Rohner T, Drago J, Lipton A, Harvey H, Simmonds M, Boucher A, Glode L M, Wettlaufer J
出版信息
Prog Clin Biol Res. 1985;185A:359-71.
PMID:4034580
Abstract
摘要
相似文献
1
2
New principles in the management of metastatic prostatic cancer.转移性前列腺癌治疗的新原则
Prog Clin Biol Res. 1985;185A:383-405.
3
[New hormonal treatments of metastatic prostatic cancer. Review of the literature].
Rev Rhum Mal Osteoartic. 1985 Oct;52(10):577-85.
4
A rat prostatic adenocarcinoma as a model for the human disease.一种作为人类疾病模型的大鼠前列腺腺癌。
Invest Urol. 1979 Jul;17(1):37-41.
5
Innovative approaches to the hormonal treatment of advanced prostate cancer.晚期前列腺癌激素治疗的创新方法。
Eur Urol. 1997;32 Suppl 3:78-80.
6
Treatment options in androgen-independent prostate cancer.雄激素非依赖性前列腺癌的治疗选择。
Cancer Invest. 1999;17(2):137-44.
7
[Treatment of estrogen-resistant forms of cancer of the prostate].
Urol Nefrol (Mosk). 1974;39(4):68-74.
8
9
Management of newly diagnosed metastatic carcinoma of the prostate.新诊断前列腺转移性癌的管理
Urol Clin North Am. 1984 May;11(2):283-95.
10
Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).用雄激素去除与Trk酪氨酸激酶抑制剂CEP-751（KT-6587）或CEP-701（KT-5555）联合治疗的Dunning H大鼠前列腺癌在体内持续消退。
Cancer Res. 1999 May 15;59(10):2395-401.
Zotero 插件